openPR Logo
Press release

Future of Glucagon-like Peptide 1 Market: Size, Share & Forecasts to 2029

08-26-2025 12:24 PM CET | Chemicals & Materials

Press release from: The Business Research Company

Glucagon-like Peptide 1 Market

Glucagon-like Peptide 1 Market

Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.

What Is the Projected Market Size Valuation of the Glucagon-like Peptide 1 Market by 2025?
The market size of glucagon-like peptide 1 has experienced a robust growth in the past few years. It is projected to increase from $20.88 billion in 2024 to $22.06 billion in 2025, progressing at a compound annual growth rate (CAGR) of 5.7%. Growth factors during the historic period include the escalating occurrence of diabetes, intensified focus on superior diabetes management, patient's inclination towards injectable treatments, clinical effectiveness and safety parameters, as well as advancements made in diabetes research.

What Is the Estimated Market Growth Value for the Glucagon-like Peptide 1 Industry in 2029?
In the coming years, the glucagon-like peptide 1 market is projected to experience robust expansion, reaching an estimated value of $30.5 billion by 2029, with a compound annual growth rate (CAGR) of 8.4%. The predicted growth within this period is due to the introduction of oral glp-1 treatments, emphasis on personalized healthcare, incorporation in diabetes management protocols, and a focus on patient-oriented healthcare strategies. In the forecast period, key trends include market outreach in developing economies, approval of new formulations by regulations, an increased concentration on personalized healthcare, enhancement of patient knowledge through educational and awareness programs, and dynamics of competitive market landscape.

Explore The Complete Report Now:
https://www.thebusinessresearchcompany.com/report/glucagon-like-peptide-1-global-market-report

What Are the Growth Drivers and Opportunities in the Glucagon-like Peptide 1 Market?
The upward trend in diabetes prevalence is predicted to boost the worldwide market for glucagon-like peptide 1. Diabetes is a health condition characterized by high levels of blood glucose or sugar. Glucagon-like peptide 1 is a prescribed medication for conditions such as type 2 diabetes, potentially aiding weight loss and lowering blood sugar levels. To illustrate, the National Library of Medicine, a US hub for biomedical informatics and computational biology, estimated in January 2022 that the global prevalence of diabetes in individuals aged between 20-79 was 10.5% (536.6 million people) in 2021, with forecasts showing an increase to 12.2% (783.2 million) by 2045. Hence, the rising incidence of diabetes is set to stimulate the glucagon-like peptide 1 market.

Get Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10830&type=smp

What Are the Primary Segments Covered in the Global Glucagon-like Peptide 1 Market Report?
The glucagon-like peptide 1 market covered in this report is segmented -

1) By Product: Trulicity, Ozempic, Victoza, Rybelsus, Other Types
2) By Route of Administration: Oral, Parenteral, Other Routes
3) By End-Users: Hospitals, Specialty Clinics, Other End Users

Subsegments:
1) By Trulicity: Injection (pre-filled pen), Dosage forms (0.75 mg, 1.5 mg, etc.)
2) By Ozempic: Injection (pre-filled pen), Dosage forms (0.5 mg, 1 mg, etc.)
3) By Victoza: Injection (pre-filled pen), Dosage forms (1.2 mg, 1.8 mg, etc.)
4) By Rybelsus: Oral tablet (3 mg, 7 mg, 14 mg)
5) By Other Types: Experimental formulations, Combination products with other medications, Alternative delivery systems

What Are the Top Growth Trends in the Glucagon-like Peptide 1 Market?
The surge in technological advancement is a significant trend taking over the global glucagon-like peptide 1 market. To retain their foothold in the market, leading companies are introducing groundbreaking technologies. For example, Novo Nordisk A/S, the acclaimed pharmaceutical company based in Denmark, introduced Wegovy in March 2024. This is the solitary, once-weekly glucagon-like peptide 1 treatment meant for weight control. Wegovy emerged successful and was proven safe and well-tolerated in the STEP Phase 3a clinical trial program. The product assists individuals dealing with obesity in attaining and sustaining weight reduction.

Customize Your Insights And Get The Full Report Here:
https://www.thebusinessresearchcompany.com/customise?id=10830&type=smp

Which Companies Are Shaping the Future of the Glucagon-like Peptide 1 Market?
Major companies operating in the glucagon-like peptide 1 market include Novo Nordisk AS, Sanofi SA, Eli Lilly and Co, AstraZeneca plc, Pfizer Inc, Boehringer Ingelheim International GmbH, F Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Baxter, Hikma Pharmaceuticals plc, Zealand Pharma A/S, Intarcia Therapeutics Inc., GlaxoSmithKline plc, Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Benemae Pharmaceutical Corporation, Adocia, Biocon, Hanmi Pharmaceutical Co Ltd, Ligand Pharmaceuticals Incorporated, Advinus Therapeutics Ltd, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd, Union Chimique Belge, Amylin Pharmaceuticals LLC, Academic Pharmaceuticals Inc, ConjuChem Biotechnologies, MannKind Corporation:, Provention Bio Inc, Regeneron Pharmaceuticals

Which Region Holds the Largest Market Share in the Glucagon-like Peptide 1 Industry?
North America was the largest region in the glucagon-like peptide 1 market in 2024. The regions covered in the glucagon-like peptide 1 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Future of Glucagon-like Peptide 1 Market: Size, Share & Forecasts to 2029 here

News-ID: 4159852 • Views:

More Releases from The Business Research Company

Segment Evaluation and Major Growth Areas in the Personalized Testing and Supplements Market
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future. Market Valuation and Expansion Forecast for Personalized Testing
Top Players and Market Competition in the Skin Microbiome Industry
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry. Projected Expansion in the Skin
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market Landscape
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory. Steady Growth Expected in Upadacitinib Market Size Through 2029 The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Market
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field. Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics

All 5 Releases


More Releases for Peptide

ShiLai Peptide to Invest $32 Million in State-of-the-Art Peptide Laboratory in H …
ShiLai Peptide's CEO, Luo Binhua, said the investment reflects the company's commitment to a "new science model" that integrates research-driven development, controlled production, and specialized customer support. ShiLai Peptide [https://retatrutidesupplier.com/], a leading provider of high-purity, customizable research peptides, announced plans to invest $32 million to build a state-of-the-art peptide research and production laboratory in Hangzhou. The facility is designed to meet world-class GMP standards, aiming to strengthen ShiLai's global supply of
Copper Peptide GHK-Cu Market: Empowering Beauty and Health Innovations with Adva …
The global copper peptide GHK-Cu market is poised for transformative growth as innovative cosmetic and pharmaceutical formulations increasingly incorporate these bioactive peptides to promote skin rejuvenation, wound healing, and overall wellness. Driven by technological advancements, growing consumer awareness of anti-aging solutions, and an expanding portfolio of product applications, the market is set to evolve rapidly in the coming years. This industry provides an in-depth analysis of market information, key growth
Shaping the Cell Penetrating Peptide Market in 2025: Innovative Peptide Drug Dis …
How Big Is the Cell Penetrating Peptide Market Expected to Be, and What Will Its Growth Rate Be? In recent times, the market size for cell penetrating peptides has expanded swiftly. The market is projected to rise from a value of $1.87 billion in 2024 to $2.16 billion in 2025, growing at a compound annual growth rate (CAGR) of 15.6%. The historic period's growth can be credited to an amplified comprehension
Cancer Peptide Drugs Market
Global Peptide Cancer Drug Market Size, Dosage, Drug Price, Sales & Clinical Trials Insight 2030 Report Highlights: • Global Peptide Cancer Drug Market Insight By Region & Indication • Global Peptide Cancer Drug Market Opportunity: > US$ 18 Billion • Approved Peptide Cancer Drugs: > 30 Drugs • Approved Peptide Cancer Drugs Sales Insights, Patent, Dosage and Price Analysis • Peptide Cancer Drugs Clinical Trials Insight By Company, Country, Indication and Phase • Insight On Peptide Cancer Drugs In Clinical Trials: >
Global Adjuvant Peptide Market Size,Share, Research and Forecast,2023-2028| Pept …
The global Adjuvant Peptide market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Adjuvant Peptide market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global
Peptide Modifications For PEGylation
PEGylation is the process of covalently attaching polyethylene glycol (PEG) polymer chains to peptides. By increasing their molecular mass and shielding them from proteolytic enzymes, PEGylation improves the pharmacokinetics of peptides and proteins. PEGylation reduces renal clearance and results in more sustained absorption after subcutaneous administration, as well as restricted distribution. PEGylations have been shown to significantly improve water solubility, biocompatibility, immunogenicity, and other physico-chemical properties. It is an established